Infliximab and adalimumab, unlike ustekinumab, increase serum KL-6 levels in Japanese patients with psoriasis
J Dermatol
.
2015 Aug;42(8):828-9.
doi: 10.1111/1346-8138.12918.
Epub 2015 Apr 28.
Authors
Koichi Yanaba
1
,
Yoshinori Umezawa
1
,
Reiko Sakakihara
1
,
Miki Chiba
1
,
Toshihiro Ito
1
,
Sota Kikuchi
1
,
Osamu Fukuchi
1
,
Akihiko Asahina
1
,
Hidehisa Saeki
2
,
Hidemi Nakagawa
1
Affiliations
1
Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.
2
Department of Dermatology, Nippon Medical School, Tokyo, Japan.
PMID:
25919324
DOI:
10.1111/1346-8138.12918
No abstract available
Publication types
Letter
Comment
MeSH terms
Adalimumab*
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Humans
Infliximab*
Psoriasis
Ustekinumab
Substances
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Infliximab
Ustekinumab
Adalimumab